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Background: The natural history of pulmonary Langerhans cell histiocytosis (PLCH) has been unclear due to the
absence of prospective studies. The rate of patients who experience an early progression of their disease is
unknown. Additionally, conflicting effects of smoking cessation on the outcome of PLCH have been reported.
Methods: In this prospective, multicentre study, 58 consecutive patients with newly diagnosed PLCH were
comprehensively evaluated over a two-year period. Our objectives were to estimate the incidence of early
progression of the disease and to evaluate the impact of smoking status on lung function outcomes. Lung function
deterioration was defined as a decrease of at least 15% in FEV1 and/or FVC and/or DLCO, compared with baseline
values. At each visit, smoking status was recorded based on the patients’ self-reports and urinary cotinine
measurements that were blinded for the patients. The cumulative incidence of lung function outcomes over time
was estimated using the non-parametric Kaplan-Meier method. Multivariate Cox models with time-dependent
covariates were used to calculate the hazards ratios of the lung function deterioration associated with smoking
status with adjustment for potential confounders.
Results: The cumulative incidence of lung function deterioration at 24 months was 38% (22% for FEV1 and DLCO,
and 9% for FVC). In the multivariate analysis, smoking status and PaO2 at inclusion were the only factors associated
with the risk of lung function deterioration. The patients’ smoking statuses markedly changed over time. Only 20%
of the patients quit using tobacco for the entire study period. Nevertheless, being a non-smoker was associated
with a decreased risk of subsequent lung function deterioration, even after adjustment for baseline predictive
factors. By serial lung computed tomography, the extent of cystic lesions increased in only 11% of patients.
Conclusions: Serial lung function evaluation on a three- to six-month basis is essential for the follow-up of patients
with recently diagnosed PLCH to identify those who experience an early progression of their disease. These patients
are highly addicted to tobacco, and robust efforts should be undertaken to include them in smoking cessation
programs.
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Pulmonary Langerhans cell histiocytosis (PLCH) is a rare
cystic disorder of unknown origin that occurs in young
adult smokers [1-3]. The disease can resolve spontan-
eously, remain stable, or progress to respiratory failure
with severe pulmonary hypertension (PH), requiring
lung transplantation [1,2,4].
The natural history of PLCH is unclear due to a lack of
prospective studies. In a long-term, multicentre, retrospective
study, we found that lung function had deteriorated in ap-
proximately half of patients during the five years of follow-up
[5]. We also found that a subgroup of patients experienced a
dramatic decline in their forced expiratory volume in 1 sec-
ond (FEV1) early after the diagnosis of their disease [5].
The triggering role of smoking in PLCH has been
highlighted by the finding that most children with systemic
LCH who develop lung involvement in adolescence or
adulthood begin smoking before this event [6]. Smoking
cessation is an essential goal for these patients, but conflict-
ing effects of smoking cessation on the outcome of the dis-
ease have been reported, particularly because the smoking
statuses of the patients have been based on self-reports,
and no surrogate markers have been used to ascertain
smoking cessation [4,5,7-12]. Furthermore, the smoking
status of the patients during follow-up has not been
assessed in these retrospective studies.
The creation of the Reference Centre for Langerhans Cell
Histiocytosis provided a unique opportunity to conduct a
longitudinal, prospective study in a cohort of patients with
newly diagnosed PLCH, who were comprehensively evalu-
ated over time. The main objectives of this study were the
following: 1) to estimate the incidence of progression early in
the course of the disease; and 2) to rigorously assess the
smoking status of the patients during follow-up and to seek




This prospective, multicentre study was conducted by the
French National Reference Centre for Langerhans Cell
Histiocytosis, in collaboration with six hospital pulmonary
departments. The inclusion period was from May 2006 to
April 2009. The study protocol was approved by the appro-
priate ethics committee in February 2006 and was regis-
tered with www.clinicaltrials.gov (NCT01225601). The
study was funded by the French Ministry of Health and the
Delegation for Clinical Research of the Assistance
Publique-Hôpitaux de Paris. The sponsors had no role in
the design, conduct, or data analysis of the study.
Study subjects
Consecutive patients 18 years of age or older who
were referred for PLCH to the participating centreswere considered eligible, provided they received no treat-
ment for their disease. The diagnosis of PLCH either was
histologically confirmed or was based on the following: 1)
an appropriate clinical setting, 2) a typical lung high-
resolution computed tomography (HRCT) showing the
combination of nodules, cavitated nodules and thick- and
thin-walled cysts, predominantly in the upper and middle
lung fields with relative sparing of lung bases; 3) a marked
predominance of alveolar macrophages in bronchoalveolar
lavage, with no lymphocytosis and no pathogen; and 4) ex-
clusion of alternative diagnoses [1,5]. The patients’ records
were systematically reviewed to confirm the PLCH diagno-
sis at the time of inclusion.
All of the patients provided written informed consent.
Additional details on the inclusion and exclusion criteria
are provided in the Additional file 1.Follow-up
The patients were managed in an outpatient manner at
each study centre. Study visits occurred at baseline and
at three, six, 12, 18, and 24 months. The patients were
strongly encouraged to stop smoking at inclusion and
during all of the follow-up visits in the study, including
the use of dedicated smoking cessation consultations at
each participating centre. The prescription of medica-
tions used in the smoking cessation programs was left to
the discretion of the physician investigators.
At each visit, clinical evaluation, smoking status (based
on the patients’ self-reports and urinary cotinine measure-
ments blinded for the patients) [13], lung function, blood
gases, and 6-minute walk test results were recorded. The
patients also completed the St George’s Respiratory Ques-
tionnaire (SGRQ) [14]. Lung HRCT and Doppler echocar-
diography (as a screening test for PH) [15] were performed
every six months. The evaluations performed at each visit
are detailed in the Additional file 1.Data collection
A standardised case report form was completed at each in-
vestigation centre. The data were monitored by independ-
ent clinical research assistants. All of the HRCT scans were
centrally analysed by a radiologist (C de M) and a chest
physician (AT), both of whom had no knowledge of the
clinical or functional findings. Semi-quantitative nodular
and cystic CT scores were calculated, and the patients were
classified into subgroups according to the CT score values,
as previously described [5]. The presence of other smoking-
related lung abnormalities (ground glass opacities and
emphysema) were also recorded [16,17]. During the follow-
ups, an HRCT score variation of at least four points was
considered significant. Additional details about the lung CT
analyses and on the scoring that was used is provided in
the Additional file 1.
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The primary outcome was the progression of PLCH,
based on lung function deterioration, defined as a de-
crease of at least 15% in FEV1, forced vital capacity
(FVC) and/or the diffusing capacity of carbon monoxide
(DLCO) compared with the baseline values.
Additionally, because prolonged constitutional symp-
toms and the occurrence of multiple pneumothoraces
were reportedly associated with poor outcomes of PLCH
[18], patients presenting these features during their
follow-up were also considered as having progressive
disease, even in the absence of the deterioration of lung
function.
Secondary outcomes included variations in the lung
function parameters over time, the 6-minute walk test
and blood gas results, HRCT findings, SGRQ scores, and
the occurrence of PH.
Statistical analysis
Descriptive statistics are presented, namely the mean ±
standard deviation (SD) or median (interquartile range
[IQR]) values.
The cumulative incidence of the lung function out-
come over time was estimated using the non-parametric
Kaplan-Meier method. Cox proportional hazards models
with time-dependent covariates were used to calculate
the cause-specific hazards ratio (HR) of lung function
deterioration associated with smoking status, while fully
adjusting for potential confounders. The time-varying
smoking patterns were modelled with three covariates:
1) the subject’s smoking status (smoker or non-smoker)
at the current visit; 2) the subject’s smoking status over
the previous six or 12 months; and 3) tobacco non-
smoker status during the entire study period.
Mixed models incorporating repeated measures over
time on the same subjects (generally correlated) were
used for the continuous outcome measurements (i.e.,
lung function parameters and HRCT scores).
All of the statistical analyses were performed using
SAS 9.3 (SAS Inc., Cary, NC, USA) and R 3.0.2 (http://




Sixty-three patients with PLCH were enrolled in the study.
Five patients were excluded (three patients were immedi-
ately lost to follow-up after inclusion, one patient withdrew
his informed consent, and one patient with lymphangio-
leiomyomatosis had been erroneously included).
The disease was isolated in the lung in all but two pa-
tients who had associated localised bone lesions. The
diagnosis of PLCH was histologically confirmed in 21
patients (36%; surgical lung biopsy, n = 20; bone biopsy,n = 1). The median time between the diagnosis of PLCH
and inclusion in the study was 3.8 months (IQR: 2–7
months). The characteristics of the patients at the time
of inclusion are shown in Table 1. No superimposed
lung HRCT ground glass opacities were observed,
whereas emphysema was present in 5 patients (localised
n = 3, diffuse n = 2, both with histologically proven
PLCH).
Doppler echocardiography was available at inclusion for
57 patients and none had criteria for PH. The median tri-
cuspid regurgitant jet velocity was 2.4 m∙s−1 (IQR 2.3-
2.5 m∙s−1), the median pulmonary arterial systolic pressure
was 30 mm Hg (IQR 26–33 mm Hg), and no patient had
increased dimensions of right heart chambers.
The patients were followed for a median of 24 months
(IQR: 22–25 months). Fifty-five and 44 patients were eva-
luable at one and two years of follow-up, respectively. One
patient incidentally died of myocardial infarction five
months after inclusion, and 13 patients discontinued the
study. No patients received systemic corticosteroids or im-
munosuppressive treatment during the study. A flow chart
of the study is provided in the Additional file 1.
Progression of PLCH
No patients complained of constitutional symptoms dur-
ing the follow-up visits. Two patients experienced
pneumothorax at one and 12 months after inclusion, re-
spectively; pneumothorax spontaneously resolved in one
case and was treated by surgical pleurodesis in the other.
No patient progressed from isolated PLCH to multi-
system disease.
Compared with their baseline values, 23 (40%) patients
had a decrease of at least 15% in FEV1, FVC and/or DLCO
within a median of one year of follow-up (Table 2). More
precisely, FEV1, FVC, and DLCO decreased by at least 15%
in 13 (22%) patients, six (10%) patients, and 14 (24%) pa-
tients, respectively. The two patients who had a pneumo-
thorax during their follow-up had previously presented a
decrease in their lung function. Figure 1 shows the cumu-
lative incidences of the deterioration of lung function pa-
rameters during the study. The estimated cumulative
incidence of deterioration at 24 months was 38% (95% CI:
25-51%) considering any functional parameter, 22% (95%
CI: 11-33%) for FEV1 and DLCO and 9% (95% CI: 1-16%)
for FVC.
Patients with lung function deterioration
Table 2 summarises the characteristics of the patients
with lung function deterioration. At the time of deterior-
ation, 17 patients (74%) had a functional class of dys-
pnoea that was ≥2 according to the New York Heart
Association (NYHA) criteria. Among the 13 patients
with a decline in FEV1, nine (69%) had an obstructive
pattern at the time of deterioration (FEV1: 66 ± 10.4% of
Table 1 Baseline characteristics of the patients*
Characteristic N = 58
Age, yrs 35.6 ± 10.8




Smoking history, pack-years 21 ± 17
At diagnosis, n (%)
Current smokers 56 (97)
Ex-smokers 2 (3)
At inclusion, n (%)
Current smokers 39 (67)




NYHA class II/III 23/2
History of pneumothorax 11 (19)
Constitutional symptoms† 6 (10)
Pulmonary function testing
FEV1
Volume, ml 2974 ± 839
% predicted 87 ± 18
FVC
Volume, ml 3787 ± 1036
% predicted 93 ± 18
FEV1/FVC, % 75.5 ± 8.8
TLC, % predicted 100.6 ± 15.3
RV, % predicted 116.5 ± 36.2
RV/TLC, % predicted 114.4 ± 30.2
DLCO, % predicted 64.3 ± 13.2
Normal lung function, n (%) 7 (12)
Restriction, n (%)‡ 5 (9)
Obstruction, n (%)‡ 15 (26)
Bronchial hyperreactivity, n (%)‡ 6 (10)
DLCO <80% predicted, n (%)‡ 49 (87)
PaO2, mm Hg 87 ± 10
6-Minute walk distance, m 514 ± 93
HRCT nodular score§ 8 ± 4.5




Table 1 Baseline characteristics of the patients*
(Continued)
HRCT cystic score§ 8.2 ± 5




Very high 2 (3)
SGRQ score║ 20.2 ± 18.8
Definition of abbreviations: IQR interquartile range, NYHA New York Heart
Association, FEV1 forced expiratory volume in 1 second, FVC forced vital
capacity, TLC total lung capacity, RV residual volume, DLCO diffusing capacity
for carbon monoxide, PaO2 arterial partial oxygen pressure, HRCT high-
resolution computed tomography, SGRQ St George’s Respiratory
Questionnaire.
*Plus-minus values are the means ± SDs.
†Constitutional symptoms were associated with respiratory symptoms in four
of six patients.
‡Lung function restriction was defined as TLC <80% of the predicted value
and obstruction as an FEV1/FVC ratio <70%. Bronchial hyperreactivity
corresponded to a post-bronchodilator FEV1 improvement of >12% and
>200 ml compared with the baseline values. The DLCO was available for
56 patients.
§HRCT was available at inclusion for 56 patients. The maximal values for the
HRCT nodular and cystic scores were 18 and 24, respectively.
║SGRQ was available at inclusion for 55 patients. The scores ranged from 0 to
100, with higher scores indicating worse functioning.
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creases in their FVC, only one patient had a restrictive pat-
tern (TLC: 70% of the predicted value), whereas the
remaining five patients had a parallel increase in their re-
sidual volume (RV), resulting in a normal TLC (TLC:
112 ± 9.5% of the predicted value). Eight patients had an
isolated decrease in DLCO (56 ± 12% of the predicted
value at the time of deterioration). Serial Doppler echo-
cardiograms were available for 7 of these 8 subjects and
showed criteria for likely PH in one patient at 18 months
of follow-up (tricuspid regurgitant jet velocity: 3.34 m∙s−1;
pulmonary arterial systolic pressure: 54 mm Hg). PH was
confirmed by right heart catheterisation (mean pulmon-
ary artery pressure: 29 mm Hg). The results of the 6-
minute walk test did not significantly vary between base-
line and the time of lung function deterioration.
Smoking statuses of the patients during the study
The smoking statuses of the patients at each visit were
based on their self-reports and their urinary cotinine mea-
surements for all of the cases, except for one patient who
was undergoing nicotine replacement therapy. Figure 2
shows the variations in the smoking statuses of the patients
over time. At inclusion, 39 patients currently smoked, and
19 patients had stopped smoking between diagnosis and
their inclusion in the study. Among these 19 non-smoking
patients at inclusion, 11 patients remained non-smokers
throughout their follow-ups in the study for a median dur-
ation of 24.2 months (IQR: 23–25 months), whereas eight
patients resumed smoking for variable periods of time.
Table 2 Characteristics of the 23 patients with deteriorating lung function*
Parameter (n) Time of
deterioration
month
Baseline Deterioration Extent of deterioration
Absolute value† Absolute value† P value‡
% of predicted %
FVC (n = 6) 14.3 (8 · 4–23) 3350 (3100–3810) 2745 (2330–2950) −665 (−770; −590) 0.03
98 (85–112) 80 (64–94) −20 (−22.6; −16.2)
FEV1 (n = 13) 12.8 (5.8–18.2) 2540 (2390–3300) 1990 (1740–2770) −460 (−530; −400) <0.001
90.1 (80; 96 · 0) 77.2 (67 · 9; 78 · 7) −16.7 (−18.8; −15.8)
DLCO (n = 14) 11.7 (6.2–17.6) 6 (4.7-6.5) 4.82 (3.6-5.31) −1.17 (−1 · 4; −0.95) <0.001
64.3 (57–72) 50 (44–60) −17.8 (−19 · 2; −16 · 3)
6-minute walk distance, m 505 (480–547) 529 (471–564) 0 (−36; +31.5) 0.71
PaO2, mm Hg 79 (75–88) 86 (79–90) −1 (−6; +12) 0.38
SGRQ score§ 21.8 (10 · 8–43 · 5) 16.1 (7.3–28.7) −3.2 (−11.2; +2.1) 0.12
HRCT nodular score║ 7.5 (6–10) 6.5 (5–10) 0 (0–0) 0.69
HRCT cystic score 6.5 (5–11) 7 (4–12) 0 (0–2) 0.18
Definition of abbreviations: FVC forced vital capacity, FEV1 forced expiratory volume in 1 second, DLCO diffusion capacity for carbon monoxide, PaO2 the arterial
partial oxygen pressure, SGRQ St George’s Respiratory Questionnaire, HRCT high-resolution computed tomography.
*Results are expressed as the medians and interquartile ranges (in parentheses). Lung function deterioration was defined as a decrease of at least 15% in the
FEV1, FVC and/or DLCO.
†Absolute values are expressed in ml for FVC and FEV1 and in mmol/min/kPa for DLCO.
‡A paired t-test was used for the comparisons.
§SGRQ was available for 22 patients. Values ranged from 0 to 100, with higher scores indicating worse functioning.
║The maximal values for the HRCT nodular and cystic scores were 18 and 24, respectively.
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sion, three patients stopped smoking transiently during
their follow-ups for three or six months, and five patients
were weaned from tobacco for six (n = 1), 12 (n = 1), 18
(n = 1), or 24 (n = 2) months. Taken together, 13 (22%)
patients remained weaned from tobacco throughout their













































Figure 1 The estimated cumulative incidence of lung function
deterioration during the study. The overall lung function
corresponds to a decrease of at least 15% in FEV1, FVC, and/or DLCO.
FEV1 = forced expiratory volume in 1 second; FVC = forced vital
capacity; DLCO = diffusion capacity for carbon monoxide.Based on their lung function parameters, there was no
difference in severity between non-smoking and smoking
patients at the time of inclusion (p > 0.1).Factors predictive of lung function deterioration
Table 3 presents the detailed univariate analyses of the fac-
tors predictive of lung function deterioration. At inclusion,
the factors that influenced the risk of lung function deteri-
oration were older age, the presence of an airflow obstruc-
tion pattern, decreased PaO2, and a high SGRQ score.
Smoking status at inclusion was also associated with an in-
creased risk of lung function deterioration. In contrast,
FEV1 impairment at inclusion, the initial presence of air
trapping (defined as an RV/TLC ratio of >120% of the pre-
dicted value), and HRCT cystic-score values were not asso-
ciated with further deterioration in lung function. When
considering the predictive factors jointly in a multivariable
model, only smoking status and PaO2 at inclusion still
influenced the hazard of lung function deterioration.
Indeed, smoking at inclusion was associated with an
increased hazard of progression (HR = 3.28; 95% CI:
1.00-11.1; p = 0.05); conversely, the higher the PaO2
level was at inclusion, the lower the risk was of pro-
gression (HR = 0.94, 95% CI: 0.90-0.98; p = 0.0036).
Notably, among the patients who smoked at inclusion,
those whose lung function deteriorated during follow-up
were older (41.4 ± 11.3 yrs vs. 32.8 ± 7.6 yrs, p = 0.016), had
lower PaO2 values (81.1 ± 9.1 mm Hg vs. 91.0 ± 7.6 mm
Hg, p = 0.0013) and had somewhat higher SGRQ scores



























Figure 2 Detailed changes in the smoking statuses of the patients during the study. The patients’ smoking statuses were recorded at each
scheduled visit based on their self-reports and urinary cotinine concentrations (except in patients using nicotine replacement therapy). Each line
represents a patient. Periods of current smoking are displayed in black, periods of smoking cessation in grey, and periods of loss to follow-up
in white.
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whose lung function did not deteriorate.
Lung function outcomes according to smoking status of
the patients
Table 4 presents the estimated effects of the patients’ smok-
ing statuses (at inclusion and over time) on lung function
deterioration. Tobacco use over time was associated with
an increased hazard of pulmonary function deterioration.
Conversely, smoking discontinuation during the study was
associated with a decreased risk of subsequent lung func-
tion deterioration, even for patients who had stopped
smoking during the previous six months. Moreover, these
effects of smoking status remained statistically significant
when adjusting for the potential confounder identified bythe multivariate prognostic analysis (i.e., PaO2 at inclusion).
In contrast, smoking status over time was not associated
with variations in the HRCT scores (data not shown).
Secondary outcomes of the study
Considering the entire study population, the mean yearly
decline in lung function parameters of the entire population
was 68 ± 90 ml (1.2 ± 1.8%) for FEV1, 43 ± 107 ml (0.1 ±
1.7%) for FVC and 0.24 ± 0.2 mmol/min/kPa (1.4 ± 1.5%)
for DLCO. However, at the last follow-up, 24 (41%) patients
had an airflow obstruction (FEV1: 68.4 ± 14.5% of the pre-
dicted value), and five (9%) patients exhibited a restrictive
pattern (TLC: 73.6 ± 4.5% of the predicted value). Notably,
these patients did not experience pneumothoraces nor have
other smoking-related interstitial lung disease features (i.e.,





HR (95% CI) P value
Demographic features
Age, yrs 41.1 ± 12.0** 32.0 ± 8.2 1.7 (1.2-2.4)† 0.002
Sex, n (%)
Male 12 (52) 15 (43) 1.0
Female 11 (48) 20 (57) 0.98 (0.4-2.3) 0.97
Smoking status, n (%)
Smokers 20 (87) 19 (54) 1.0
Non-smokers 3 (13) 16 (46) 0.25 (0.1-0.85) 0.027
Clinical features, n (%)
Asymptomatic 6 (26) 15 (43) 0.6 (0.2-1.7) 0.38
Cough 10 (48) 10 (34) 1.3 (0.5-3.2) 0.54
Dyspnoea 13 (57) 12 (34) 2.0 (0.8-4.6) 0.11
Lung function parameters
FEV1
% predicted 85.9 ± 13.7 87.8 ± 20.4 0.9 (0.7-1.2)† 0.45
≤59% predicted, n (%) 5 (14) 1 (4) 1 · 0
60-79% of predicted 7 (20) 6 (26) 2.8 (0.3-23.3) 0.35
≥80% predicted 23 (66) 16 (70) 2.6 (0.3-19.7) 0.36
FVC
% predicted 92.4 ± 19.6 93.4 ± 17.1 0.9 (0.7-1.2)† 0.92
TLC
% predicted 101.0 ± 18.0 100.3 ± 13.4 1.0 (0.8-1.3)† 0.98
Restriction, n (%)‡ 3 (13) 2 (6) 1.9 (0.5-6.4) 0.32
RV
% predicted 118.8 ± 33.4 115.0 ± 38.4 1.0 (0.9-1.1)† 0.67
RV/TLC 36.1 ± 9.6 32.0 ± 9.6 1.0 (1.0-1.02) 0.58
Air trapping, n (%)‡ 10 (43) 11 (32) 1.7 (0.7-3.9) 0.23
FEV1 /FVC 74.1 ± 9.8 76.5 ± 8.1 0.98 (0.9-1.0) 0.42
Airflow obstruction, n (%)‡ 10 (43) 5 (14) 2.9 (1.3-6.8) 0.014
DLCO
% predicted 63.8 ± 12.9 64.6 ± 13.2 0.3 (0.0-9.3)† 0.50
<72% predicted, n (%) 17 (74) 24 (69) 1.0
≥72% predicted 6 (26) 11 (31) 0.7 (0.3-1.7) 0.42
6-Minute walk distance, m
% of the predicted value 78.7 ± 14.0 73.2 ± 10.1 1.4 (0.9-2.0)† 0.09
PaO2 81.4 ± 9.7 90.8 ± 9.0 0.94 (0.91-0.98)† 0.0014
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Table 3 Univariate analyses of the predictive factors (measured at inclusion) of lung function deterioration* (Continued)
Lung HRCT§
Nodular score 8.4 ± 4.8 7.8 ± 4.3 1.1 (0.7-2.0)║ 0.46
Cystic score 8.0 ± 3.9 8.4 ± 5.7 1.0 (0.7-1.4)║ 0.89
SGRQ score 25.7 ± 20.1 15.1 ± 16.8 1.3 (1.1-1.6)† 0.012
Definition of abbreviations: HR hazard ratio, CI confidence interval, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, TLC total lung capacity,
RV residual volume, DLCO diffusion capacity for carbon monoxide, PaO2 arterial partial oxygen pressure, HRCT high-resolution computed tomography, SGRQ St
George’s ;Respiratory Questionnaire.
*Lung function deterioration was defined by a decrease of at least 15% in FEV1, FVC and/or DLCO compared with the baseline values.
**Plus-minus values are the means ± SDs.
†Reported HRs are given for an increase of 10 units.
‡Lung function restriction was defined as a TLC <80% of the predicted value, air trapping as an RV/TLC ratio >120% of the predicted value and obstruction as an
FEV1/FVC ratio <70%.
§HRCT was available at inclusion for 56 patients (22 and 34 patients in each group). The maximal values for the HRCT nodular and cystic scores were 18 and
24, respectively.
║Reported HRs are given for an increase of 4 points.
¶SGRQ was available for 55 patients at inclusion (23 and 32 patients in each group). The scores ranged from 0 to 100, with higher scores indicating
worse functioning.
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during during their follow-up. Six patients had a PaO2 of
<70 mm Hg (61 ± 10 mm Hg) at the last evaluation.
Among the 52 patients who had serial Doppler echo-
cardiograms, with the exception of the patient described
above, no other patient exhibited criteria for PH.
Figure 3 displays the variations in the lung HRCT
scores during the study. At 24 months, the cumulative
incidence of cystic score deterioration was estimated to
be 10.7% (95% CI: 2.5-19%). Additional details about the
variations in the secondary outcomes over time are pro-
vided in the Additional file 1.
Discussion
This multicentre, prospective study evaluated the early
outcome of a homogeneous cohort of patients with un-
treated PLCH. We were able to demonstrate that 1) a
substantial proportion of patients experienced an im-
portant decline in their lung function parameters within
two years of follow-up and 2) the smoking status of the
patients was associated with the risk of subsequent lung
function deterioration.Table 4 Estimated effects of the smoking status at baseline a
deterioration*
Smoking status HR (95% CI)
Unadjusted
Baseline non-smoking 0.25 (0.07-0.85)
Time-dependent non-smoking 0.25 (0.08-0.97)
No smoking during the past six months 0.25 (0.07-0.84)
No smoking during the past 12 months 0.23 (0.07-0.79)
No smoking during the study period 0.22 (0.06-0.73)
Definition of abbreviations: FEV1 forced expiratory volume in 1 second, FVC forced vi
CI confidence interval.
*Lung function deterioration was defined as a decrease of at least 15% in FEV1, FVC
†The adjustment predictive factor at inclusion was baseline PaO2, as selected by thAll of the subjects had recent PLCH, as evidenced by
the high percentage of initially asymptomatic patients
and the low impairment of lung function at inclusion.
Similarly, the HRCT findings were also characteristic of
recent disease because all of the patients had nodular le-
sions, whereas less than 15% had high HRCT cystic
scores [5,19].
Considering the entire study population, lung function
varied weakly during the study period, as exemplified by
the mean yearly decline in lung function parameters. Strik-
ingly, however, 40% of the patients presented a decrease of
at least 15% in FEV1, FVC and/or DLCO within a median
of one year of follow-up. Although the decreases in FVC,
FEV1, and DLCO were equally significant, decreases were
more frequent for the last two parameters. The magnitude
of the FEV1 decrease in this subgroup of patients was be-
yond that observed in currently smoking COPD patients
[20], and thus probably reflected bronchiolar damage
caused by LCH lesions [2,3].
In accordance with the results of retrospective studies,
we found, in univariate analyses, that older age and the
presence of airflow obstruction at inclusion were associatednd over time on the hazard of subsequent lung function
P value HR (95% CI) P value
Adjusted†
0.027 0.30 (0.09-1.00) 0.05
0.04 0.34 (0.10-1.14) 0.08
0.025 0.29 (0.08-0.97) 0.044
0.020 0.28 (0.08-0.97) 0.045
0.014 0.28 (0.08-0.94) 0.040
tal capacity, DLCO diffusion capacity for carbon monoxide, HR hazard ratio,
and/or DLCO compared with the baseline values.























No. at Risk 54 54 49 4139
Nodular               Cystic
Figure 3 Variations in the lung HRCT scores at the different
scheduled visits of the study. The data are expressed as the
means ± SEMs of the lung HRCT nodular and cystic scores. The lung
HRCT was available at inclusion for 56 patients. The maximal values
for the HRCT nodular and cystic scores are 18 and 24, respectively.
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creased PaO2 and an altered respiratory quality of life, as
assessed by the SGRQ, were also associated with an in-
creased risk of lung function deterioration. In contrast, we
did not confirm that a decrease in FEV1 or DLCO or the
presence of air trapping was associated with a poor out-
come [5,11,18,21]. These differences were most likely due
to the heterogeneity of the patients included in the retro-
spective studies, particularly concerning the duration of
their disease [5,11,18,21]. Furthermore, in the multivariate
analysis, only baseline PaO2 remained associated with dis-
ease progression. We hypothesize that the reason behind
this correlation was that lower PaO2 may reflect more im-
paired gas exchange in the lung and/or pulmonary
vascular involvement in some patients. Finally, the 6-
minute walk test was not associated with lung func-
tion deterioration.
Based on both self-reports and blinded urinary cotinine
measurements, the smoking status of the patients mark-
edly changed over time, and only a minority (approxi-
mately 20%) were weaned from tobacco during the study
period. The significant variations in smoking status over
time most likely explained the discrepancies reported in
previous studies concerning the effects of smoking on the
outcomes of the disease [4,5,7-12]. Here, using appropriate,
time-dependent Cox models, we formally showed that a
non-smoker status was associated with a decreased risk of
subsequent lung-function deterioration, even in patients
who stopped smoking for at least six months duringfollow-up. Importantly, this effect on lung function out-
come persisted even after adjusting for PaO2 at inclusion.
Of note, no differences in the severity of baseline lung
function were observed between non-smoking and smok-
ing patients. In contrast, smoking status over time was not
associated with variations in HRCT findings.
Airflow obstruction was the predominant lung function
profile observed in the entire study population, whereas
true lung restriction, based on the TLC measured by pleth-
ysmography, was observed in less than 10% of the patients.
Notably, these patients did not experience pneumothoraces
nor have other smoking-related interstitial lung disease fea-
tures (i.e., ground glass opacities) superimposed on their
lung HRCT during their follow-up. By serial plethysmogra-
phy, patients with a decreased FVC had a parallel increase
in their RV, as previously observed in bronchiolar disorders
[22]. Although PH has primarily been described in patients
with longstanding PLCH [23-25], we found here that such
complications may rarely occur earlier in the disease
course.
Finally, whereas constitutional symptoms and the occur-
rence of pneumothoraces were reportedly associated with
poor outcomes of PLCH [18], we did not observe constitu-
tional symptoms during follow-up in patients with isolated
lung involvement, whereas pneumothoraces occurred
rarely during follow-up.
This study has some limitations. Although recruiting a
cohort of 58 patients with newly diagnosed PLCH over a
period of three years was a challenge, given the size of
the cohort, one could fail to identify factors with a
minor influence on the outcome of the disease.
Conclusions
Because lung function can deteriorate early during the
course of recent PLCH in a substantial proportion of pa-
tients and is difficult to predict in an individual patient, it
is important to evaluate patients serially using FEV1, FVC,
and DLCO measurements on a three- to six-month basis.
An isolated decreased DLCO should prompt screening for
PH by Doppler echocardiography. Whereas lung HRCT is
essential for diagnosis, systematic close sequential lung
HRCTs are of limited value. The 6-minute walk test ap-
pears to be less informative than in patients with advanced
disease [25]. Given the strong tobacco addictions of pa-
tients with PLCH, robust efforts should be undertaken to
include these patients in smoking cessation programs.Additional file
Additional file 1: Supplementary material. Supplementary methods,
results (Table S1) and figure legends. Figure S1A. Flow chart of the
study. Figure S1B. Visit calendar of the study. Figure S2. Patient
distribution among the subgroups based on lung HRCT nodular (Panel A)
and cystic scores (Panel B) during the study.
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